Wishing our friends, partners and customers in China and elsewhere a prosperous and
peaceful year ahead.
Posted by Gabriel Freitas ⎜Dec 31, 2022 ⎜ Industry
isoSolutions will be attending the EANM Annual Meeting to be held, on October 15-19, 2022, in Barcelona, Spain. Arun Singh, the CEO, hopes to see you there. If you would like to arrange a time and place to meet him, please contact :
isoSolutions will be attending the United Pharmacy Partners (UPPI) Annual Meeting on September 14-15 in Charlotte, NC. We are excited to be a part of the event where we will be joined by our partner Elysia-raytest to highlight the Full QC Solution for Radiopharmacy in our presentation on Thursday, September 15th. Neil Shirley, Sales Manager for USA and Canada, hopes to see you there. If you would like to arrange a meeting with Neil during the event, please contact him at: email@example.com(more…)
isoSolutions is pleased to announce that we will be participating in the SNMMI Annual Meeting, the world‚Äôs largest event focused exclusively on meeting the educational and networking needs of the nuclear medicine and molecular imaging community. So please drop by at Booth # 1641 to say hello, and let‚Äôs chat!
We may be contacted at firstname.lastname@example.org and we would be happy to arrange a meeting to discuss your requirements.
Tuesday, February 1st, 2022, and celebrations culminate with the Lantern Festival on February 15th, 2022.
Wishing you a prosperous and successful 2022. Happy Chinese New Year from Team isoSolutions!
The Canadian Association of Nuclear Medicine (CANM) has announced new dates for their 2022 Annual conference. It will now be held Sept 28-Oct 02, 2022 in Montreal, Quebec. Marvin Calderon or Patricia Acton, Sales Leaders, will be pleased to meet you there. They can be reached at:
Marvin Calderon: email@example.com
Patricia Acton: firstname.lastname@example.org
Additional information about CANM: https://www.canm-acmn.ca/
SNMMI 2022 Annual Meeting June 11-14, 2022 in Vancouver, BC, Canada. The SNMMI Annual Meeting is the world‚Äôs largest event focused exclusively on meeting the educational and networking needs of the nuclear medicine and molecular imaging community. Over 3,600 professional attendees are expected to participate in this meeting. isoSolutions will be excited to see you in person!
We look forward to seeing you in Vancouver, B.C.
isoSolutions is glad to announce the next Virtual meeting for CANM will be on November 6th, 2021. One-day conference.
Posted by Marvin Calderon ⎜Jul 8, 2021 ⎜ Industry
Background: In patients with oligometastatic recurrent prostate cancer, standard treatment is androgen deprivation therapy (ADT). However, ADT has many potential side effects that may result in impaired quality of life. Early identification to select patients suitable for stereotactic ablative radiotherapy (SABR) is of utmost importance to prevent or delay start of ADT and its side effects.
Because Prostate-Specific Membrane Antigen-11- Positron Emission Tomography (PSMA-11-PET) has a higher sensitivity than choline-PET, we hypothesise that PSMA-11-PET based SABR results in longer response duration and subsequent longer delay in starting ADT than choline-PET.
Patients with oligometastatic (‚â§4 metastases) recurrent prostate cancer (with no local recurrence) based on PSMA-11-PET or choline-PET treated with SABR from January 2012 until December 2017 were included. Primary endpoint was ADT-free survival. Secondary endpoints were Prostate Specific Antigen (PSA) response after SABR and time to PSA rise after SABR.
Results: Fifty patients (n = 40 PSMA-11-PET and n = 10 choline-PET) with in total 72 lesions were included. Median follow-up was 24.3 months. PSMA-11-PET enabled eligibility of patients with lower PSA levels than choline-PET (median 1.8 versus 4.2 ng/mL, p = 0.03). The PSMA-11-PET group had a significant longer PSA response duration (median 34.0 months (95% confidence interval (CI), 16.0‚Äì52.0) versus 14.7 months (95% CI 4.7‚Äì24.7), p = 0.004) with a subsequent longer ADT-free survival (median 32.7 months (95% CI, 20.8‚Äì44.5) versus 14.9 months (95% CI, 5.7‚Äì24.1), p = 0.01).
With PSMA-11-PET we are able to select patients with oligometastatic recurrent prostate cancer suitable for SABR in an earlier disease stage at lower PSA levels. PSMA-11-PET guided SABR resulted in a significant longer response duration and ADT-free survival compared with choline-PET and can therefore prevent or delay ADT related side effects.
Posted by Lizeth ⎜Mar 10, 2021 ⎜ Company
isoSolutions Marketing & Management Inc. has been recognized for sponsoring over $5000 to the Lifetime Giving program of the Langara College Foundation.
David Drummond, Founder and President of isoSolutions, acknowledged the company‚Äôs commitment ‚ÄúisoSolutions values its association with the Langara College Foundation and will continue to support initiatives aimed at enabling success of students. We stay committed to doing our bit to nurture our community ties.‚Äù
Langara College Foundation is a community of donors and volunteers who are committed to expanding educational opportunities for students by supporting scholarship and bursaries, expanding delivery of student services and campus facilities, and funding beyond the classroom experiences. Additional information can be found at (https://langara.ca/foundation/)
Posted by Lizeth ⎜Mar 9, 2021 ⎜ Industry
The Canadian Association of Nuclear Medicine (CANM) Executive Director, H√©l√®ne Samson, retired on March 1, 2021. The CANM will be under the management of NAD Marketing Inc. with Nicolas Rondeau Lapierre the General Manager. Effective immediately the CANM will have a new office location and address, however the email and website addresses remain the same.
Rosem√®re Qu√©bec, Canada J7A 4B6
The EANM‚Äô21 Congress and its Pre-Congress Symposia will be virtual.
The times stated refer to the timezone CEST (Central European Summer Time).
Pre-Congress Symposia: October 4-6 & October 11-13, 2021
Main Congress: October 20 ‚Äì 23, 2021
Posted by Lizeth ⎜Feb 10, 2021 ⎜ Calendar
February 12th, 2021, and celebrations culminate with the Lantern Festival on February 26th, 2021. Chinese New Year marks the transition between zodiac signs 2021 is the year of the Ox. Like isoSolutions, Oxen are known for strength, dependability, and patience. Happy Chinese New Year from Team isoSolutions! Wishing you a prosperous 2021!
Posted by Patricia Acton ⎜Dec 1, 2020 ⎜ Calendar
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced its 2021 Annual Meeting, June 12 ‚Äì 15, Washington, D.C. Recognizing that travel may not be possible, SNMMI is currently planning to offer a hybrid approach for the 2021 meeting. Both an in-person and virtual option will be provided, with the understanding that if conditions warrant, the meeting may transition to a 100% virtual event. As details are available they will be posted on (https://am.snmmi.org/iMIS/SNMMI-AM) . isoSolutions looks forward to its involvement in this upcoming Annual Meeting and will continue to work with SNMMI as exhibit options are developed.
Posted by Patricia Acton ⎜Dec 1, 2020 ⎜ Calendar
CANM 2021 Annual Meeting ‚Äì New dates!
The Board of the CANM and the Scientific Committee are happy to inform you that the CANM 2021 Annual Conference will take place at the Marriott Harbourfront Hotel in Halifax, September 30-October 2.
It has been moved from April to the Fall in order to have greater chances to host a live conference in 2021. Of course, should restrictions from Covid-19 still apply, the Association will revert to virtual sessions.
Please click here to view revised information regarding the 2021 conference: call for abstracts, emeritus award, hotel information, exhibitors‚Äô information. Please consult the CANM Website regularly at www.canm-acmn.ca for updates.
Posted by David T. Drummond ⎜Oct 2, 2020 ⎜ Company
isoSolutions Marketing and Management Inc. announces that Mr. David Drummond, Founder, and Managing Director, has decided to retire from the routine affairs of the company. He will continue to participate in the company as Strategic Consultant and President. The company is pleased to announce that Mr. Arun Kumar Singh, MSc MBA CSSMBB MCPM PMP, has replaced Mr. Drummond as Managing Director of isoSolutions. The owner of isoSolutions, Mr. Mark McCooey, stated: ‚ÄúisoSolutions remains committed to all of the business values instilled by David over the years of exemplary service. I am pleased Arun has joined isoSolutions and am confident that he will lead the company into an exciting future.”
Posted by Marvin Calderon ⎜Jun 3, 2020 ⎜ Industry
TORONTO ‚Äì June 3, 2020) ‚Äì The Nuclear Innovation Institute (NII) and Canadian Nuclear Isotope Council (CNIC) have partnered in an innovative study to identify challenges and evaluate potential technology, logistical, regulatory and policy solutions in Canada‚Äôs medical isotope supply chain.
Canada is a Leader in the production and Global supply of Isotopes. During the COVID-19 Pandemic, this has been never been more evident supplying critical Isotopes for medical equipment sterilization and the diagnosis and treatment of cancer.(more…)
Posted by Patricia Acton ⎜Feb 11, 2020 ⎜ Company
TORONTO ‚Äì February 11, 2020 isoSolutions Marketing & Management Inc. (isoSolutions), an innovative one stop shop when it comes to nuclear medicine products has joined a growing list of organizations as members of the Canadian Nuclear Isotope Council (CNIC) an independent body made up of representatives from the Canadian health sector, nuclear industry and leading research groups, convened to promote Canada‚Äôs role in the production of the world‚Äôs supply of radioisotopes.(more…)
Posted by Marvin Calderon ⎜Feb 7, 2020 ⎜ Industry
Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose.(more…)
Posted by David T. Drummond ⎜Oct 14, 2019 ⎜ Industry
BARCELONA, Spain, 13th October 2019 ‚Äì McMaster University‚Äôs Nuclear Reactor (CAN) and NRG (NL) announced today a unique collaboration between the Netherlands and Canada in the field of nuclear medicine.
Working together, these two globally renowned research reactors will provide the world with the highest quality radioiodine (I-125), used for the treatment of prostate and other various types of cancers, at the highest level of reliability.
The importance of readily available medical isotopes
Posted by Hans Peng ⎜Aug 19, 2019 ⎜ Calendar
The 13th National Conference of Nuclear Medicine and 2019 Annual meeting of Chinese Nuclear Medicine will take place in Kunming, Yunnan from 2019 September 19-22.
isoSolutions Marketing and Management‚Äôs Sales and Marketing Representative, China, Eric Huang (ÈªÑÁª¥Ë∂Ö) will be attending the conference. If you would like to arrange a time to meet with Eric, please contact him at email@example.com or +86-186 21264608
Posted by David T. Drummond ⎜Jul 17, 2019 ⎜ Company
isoSolutions was very pleased to welcome to its Vancouver office a visitor from the Abetavu children‚Äôs home in Uganda. Abetavu is a charity that isoSolutions has supported for several years. Our visitor from Abetavu ‚Äì Ms. Tinah Praise ‚Äì entered the Abetavu home in Uganda when she was 9 year old. She is now entering her second year of college in Kabale, Uganda.
Abetavu is an organization that started as an orphanage, founded by a Vancouver woman, Carli Travers, and her Ugandan husband Robert, nearly ten years ago. It is now so much more than an orphanage. Abetavu provides a safe haven to children that need support, and it provides essential services to the local community, in terms of counseling, education, sports, and many other services. Tinah is so grateful for having a chance at an education, something none of her other ten siblings were able to have. (more…)
Posted by David T. Drummond ⎜Jun 9, 2019 ⎜ Calendar
11th International Symposium on Targeted-Alpha-Therapy, April 1-5, 2019 in Ottawa, Ontario, Canada. isoSolutions is pleased to inform you that we will attend the 11th International Symposium on Targeted-Alpha-Therapy (TAT11). You can find us at booth 28 the Exhibit Hall at the Fairmont Chateau Laurier.
Neil Shirley, Sales Manager, United States and Canada, hopes to see you there. If you would like to arrange a time to meet with Neil, please contact him at firstname.lastname@example.org
Hope to see you in Ottawa, Ontario.
Posted by David T. Drummond ⎜Jun 8, 2019 ⎜ Calendar
SNMMI 2019 Annual Meeting, June 22-25, 2019 in Anaheim, California.
isoSolutions is pleased to inform you that we will attend the¬†Annual Meeting of the Society of Nuclear Medicine and¬†Molecular Imaging (SNMMI). (more…)
Posted by David T. Drummond ⎜Apr 25, 2019 ⎜ Company
In order to strengthen its position in the Asian market, isoSolutions has appointed a Sales and Marketing Manager for Asia. Mr. Eric Chang will be responsible for sales and marketing efforts in the Asian market. He will be supported by Mr. Hans Peng, Sales and Marketing Manager, China and Mr. Eric Huang, Sales and Marketing Representative, China (located in Shanghai). (more…)
Posted by David T. Drummond ⎜Apr 22, 2019 ⎜ Industry
Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR) expression. Targeting proteins that are expressed as a down-stream effect of AR activity is a promising rationale for management of this disease. (more…)
Posted by Kevin Yang ⎜Mar 25, 2019 ⎜ Industry
5D3 is a new high-affinity murine monoclonal antibody specific for prostate-specific membrane antigen (PSMA). PSMA is a target for the imaging and therapy of prostate cancer. 111In-labeled antibodies have been used as surrogates for 177Lu/90Y-labeled therapeutics. We characterized 111In-DOTA-5D3 by SPECT/CT imaging, tissue biodistribution studies, and dosimetry.
Posted by Kevin Yang ⎜Feb 25, 2019 ⎜ Industry
The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of combined capecitabine and 177Lu-DOTATATE in malignant PGL patients. (more…)
Posted by David T. Drummond ⎜Feb 21, 2019 ⎜ Industry
Academic journals have published a large number of papers in the therapeutic nuclear medicine (NM) research field in the last 10 years. Despite this, a literature analysis has never before been made to point out the research interest in therapeutic radionuclides (RNs). For this reason, the present study aims specifically to analyze the research output on therapeutic radiometals from 2008 to 2018, with intent to quantify and identify global trends in scientific literature and emphasize the interdisciplinary nature of this research field. (more…)
Posted by David T. Drummond ⎜Feb 18, 2019 ⎜ Company
Vancouver and Buenos Aires, February 2019
We are very proud to announce a new strategic commercial Alliance between isoSolutions and Fenix Medica for the Latin American market. isoSolutions provides a one-stop shopping service as well as technical support worldwide for nuclear medicine products including: Radiochemicals, Stable isotopes, Labeled compounds, Sealed sources, Synthesizers, QC instruments, and Shielding products. (more…)
Tags: Latin America
Posted by Kevin Yang ⎜Feb 13, 2019 ⎜ Industry
Bone fracture healing is dependent upon the rapid migration and engraftment of bone marrow (BM) progenitor and stem cells to the site of injury. Stromal cell-derived factor-1 plays a crucial role in recruiting BM cells expressing its receptor CXCR4. Recently, a CXCR4 antagonist, plerixafor, has been used to mobilize BM cells into the blood in efforts to enhance cell migration to sites of injury presumably improving healing. (more…)
Posted by David T. Drummond ⎜Feb 5, 2019 ⎜ Company
Chinese Lunar New Year
isoSolutions wishes everyone health and prosperity in the Year of the Pig!
Posted by Marvin Calderon ⎜Jan 13, 2019 ⎜ Calendar
isoSolutions will be attending the ALASBIMN 2019 Annual Meeting to be held in Lima, Peru November 13 to 16, 2019. Marvin Calderon, Regional Sales and Marketing Manager Sales for Latin America hopes to see you there. If you would like to arrange a time and place to meet him, please contact¬†email@example.com.
Posted by Patricia Acton ⎜Jan 13, 2019 ⎜ Calendar
isoSolutions will be attending the CANM 2019 Annual Meeting to be held in Qu√©bec, QC, Canada February 07 to 09, 2019. Pat Acton, Regional Sales and Marketing Manager Sales for Canada and US hopes to see you there. If you would like to arrange a time and place to meet her, please contact¬†firstname.lastname@example.org.
Posted by David T. Drummond ⎜Nov 20, 2018 ⎜ Industry
The worldwide supply of molybdenum-99 is expected to stabilize over the next several weeks as the High Flux Reactor in the Netherlands and the Open Pool Australian Lightwater nuclear reactor have resumed operations and are expected to reach normal Mo-99 production this week. Meanwhile, NTP Radioisotopes’ South Africa-based Pelindaba Nuclear Plant, which has finished functionality tests, is awaiting approval from the country’s National Nuclear Regulator to begin Mo-99 production runs.
Posted by Kevin Yang ⎜Nov 5, 2018 ⎜ Industry
Radiolabeled somatostatin analog therapy has become an established treatment method for patients with well to moderately differentiated unresectable or metastatic neuroendocrine tumors (NETs). The most frequently used somatostatin analogs in clinical practice are octreotide and octreotate. (more…)
Posted by David T. Drummond ⎜Oct 29, 2018 ⎜ Industry
A generous donor has given the B.C. Cancer Foundation $18.346 million, but insists on remaining anonymous.
“Today marks an important moment in cancer research and care in Canada with one of the largest donations ever made to bring new treatment solutions to patients,” said¬†Sarah Roth, president and¬†CEO of the¬†B.C.¬†Cancer Foundation. (more…)
Posted by Kevin Yang ⎜Sep 21, 2018 ⎜ Industry
INTRODUCTION: Prostate-specific membrane antigen (PSMA) is an excellent prostate cancer target for theranostic applications. Many imaging agents showing high sensitivity/specificity for PSMA-expressing tissues have been developed. Some have been labeled with therapeutic radionuclides (i.e. 177Lu, 225Ac) and have had success in treating castration-resistant metastatic prostate cancer. The activity administered to patients is limited by toxicity to normal organs;
Posted by Kevin Yang ⎜Sep 12, 2018 ⎜ Industry
This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EBPSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted. (more…)
Posted by Kevin Yang ⎜Sep 6, 2018 ⎜ Industry
Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide. Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by prostate tumors and has been shown to be a valid target for internal radionuclide therapy in both preclinical and clinical settings. The most common radiotherapeutic agent is the small molecule 177Lu-PSMA-617, (more…)
Posted by Patricia Acton ⎜Sep 5, 2018 ⎜ Calendar
isoSolutions will be attending the United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting to be held in San Antonio, TX September 12 to 15, 2018. (more…)
Tags: Batch Reporting System Beta detection Beta flow monitor Beta radio-detector Cassette-based synthesis Chromatography Software Clarity Elysia-raytest Ga-68 synthesis Gamma detection Gamma flow monitor Gamma radio-detector Gamma spectroscopy Gas Chromatography GC systems HPLC isoSolutions LIMS Liquid Scintillation Liquid Scintillation Pump Lu-177 MCA Multichannel analyzer North America Nuclear Medicine PET QC QC-Cubicle Quality Control Radio Detector Radio nuclide identification Radio nuclide purity radio spectroscopy radio TLC scanners radio-flow monitor radio-HPLC radio-synthesis radio-TLC Systems Radio-tracer Radiopharmaceutical Tracer Radiopharmaceuticals Radiopharmacy Residual Solvents Control Single-use cassette synthesis SPECT QC Spectroscopy Software Sterile filter integrity test Sterility Filter Test Synthesis Modules Synthesizers Tradeshows UPPI
Posted by Hans Peng ⎜Aug 2, 2018 ⎜ Industry
Since China was the highlighted country of 2018 SNMMI in Philadelphia, several CSNM board members presented a brief report of 2018 SNMMI to the audience. One interesting fact needs attention is that Lu-177 is the most discussed topic this year not only because Lu-177 is highly in demand during SNMMI, but also more and more professors and doctors in China have realized how important and effective Lu-177 is when it is used to diagnose and treat prostate cancer. (more…)
Posted by Kevin Yang ⎜Jul 26, 2018 ⎜ Industry
Y-90 radioembolization for HCC patients with PVT appears to have an acceptable safety profile, with better survival in CP-A patients than in CP-B patients. This study confirms prior reports of survival in PVT patients treated with Y-90 radioembolization, and survival after Y-90 radioembolization appears to exceed that in
similar patients treated with systemic therapies. Despite the negative studies recently reported, Y-90 radioembolization is a reasonable treatment option in properly selected PVT patients. Further controlled studies are needed to compare it with systemic therapies or other locoregional treatments for advanced-stage HCC.
Nadine Abouchaleh1, Ahmed Gabr1, Rehan Ali1, Ali Al Asadi1, Ronald A. Mora1, Joseph Ralph Kallini1, Samdeep Mouli1, Ahsun Riaz1, Robert J Lewandowski1, and Riad Salem1‚Äì3
Info on purchasing Y-90, please contact email@example.com
Read the full article PDF
Posted by Hans Peng ⎜Jul 11, 2018 ⎜ Calendar
The Chinese Society of Nuclear Medicine Annual Meeting will be held¬†in Chengdu, Sichuan from 2018‚Äì07‚Äì12 to 2018‚Äì07‚Äì15. We hope to see you there and we can arrange a time and place to meet if you wish.
Posted by Hans Peng ⎜Jul 11, 2018 ⎜ Industry
isoSolutions Marketing and Management will send its representative in China, Eric Huang to the 19th China Cardiovascular and Nuclear Medicine Annual meeting organized by Chinese Society of Nuclear Medicine (http://www.csnm.com.cn/) in Sichuan, China.
The 19th China Cardiovascular and Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from July 12 to July 15, 2018. (more…)
Posted by David T. Drummond ⎜Jun 29, 2018 ⎜ Industry
PHILADELPHIA (Embargoed until 6:30 p.m. EDT, Tuesday, June 26, 2018) ‚Äì In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). (more…)
Posted by David T. Drummond ⎜Jun 11, 2018 ⎜ Industry
By Wayne Forrest, AuntMinnie.com staff writer.
Major changes are taking place in the intricate network that supplies healthcare providers around the world with molybdenum-99 (Mo-99), a key radioisotope for nuclear medicine studies. The question is, can the nuclear medicine community avoid another devastating shutdown like the one that occurred in 2009? (more…)
Posted by Kevin Yang ⎜Jun 6, 2018 ⎜ Industry
A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617. Swimmer-plot analysis indicates a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia was the main reason patients discontinued therapy or refused additional administrations and was in the same dimension as nonresponse; this finding indicates that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range.
Clemens Kratochwil1, Frank Bruchertseifer2, Hendrik Rathke1, Markus Hohenfellner3, Frederik L. Giesel1, Uwe Haberkorn*1,4, and Alfred Morgenstern*2
Info on purchasing Ac-225, please contact firstname.lastname@example.org .
Posted by David T. Drummond ⎜May 7, 2018 ⎜ Industry
The Armstrong-Lepeska Science Marketing Scholarship, sponsored by isoSolutions, has been awarded to two more students. This scholarship is granted to a student at Langara College in Vancouver.¬† To highlight the importance of marketing and sales of high-technology, scientifically-intensive products, the scholarship awards a student in a scientific discipline who completes a course in Marketing.
Posted by David T. Drummond ⎜Apr 25, 2018 ⎜ Industry
PET/CT-guided percutaneous biopsy can be safely and accurately performed within the PET/CT suite without reinjection of the¬†89Zr-labeled radiotracer after the initial injection for diagnostic imaging.¬†89Zr-labeled radiotracers targeting specific proteins may be useful for both detection and molecular profiling in high-risk patients presenting with widely disseminated disease. Studies such as this may add clinical justification for the use of molecular imaging in interventional oncology and for promoting future access to interventional PET imaging facilities. (more…)
Posted by David T. Drummond ⎜Apr 6, 2018 ⎜ Industry
Key findings of the study: